{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T03:43:23Z","timestamp":1792035803081,"version":"4.4.0"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Virology"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1016\/j.coviro.2014.08.004","type":"journal-article","created":{"date-parts":[[2014,9,18]],"date-time":"2014-09-18T00:00:38Z","timestamp":1410998438000},"page":"1-7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"special_numbering":"C","title":["Inhibition of viral RNA polymerases by nucleoside and nucleotide analogs: therapeutic applications against positive-strand RNA viruses beyond hepatitis C virus"],"prefix":"10.1016","volume":"9","author":[{"given":"Jerome","family":"Deval","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian A","family":"Symons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo","family":"Beigelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coviro.2014.08.004_bib0005","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nrmicro1645","article-title":"Replication of hepatitis C virus","volume":"5","author":"Moradpour","year":"2007","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.coviro.2014.08.004_bib0010","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1056\/NEJMe1100829","article-title":"A new era of hepatitis C therapy begins","volume":"364","author":"Jensen","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coviro.2014.08.004_bib0015","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa1013086","article-title":"Telaprevir for retreatment of HCV infection","volume":"364","author":"Zeuzem","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coviro.2014.08.004_bib0020","series-title":"Hepatitis C Virus and its Inhibitors: The Polymerase as a Target for Nucleoside and Nucleotide Analogs. Cancer-causing Viruses and Their Inhibitors","first-page":"41","author":"Deval","year":"2014"},{"key":"10.1016\/j.coviro.2014.08.004_sbref0025","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/13305","article-title":"Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site","volume":"6","author":"Lesburg","year":"1999","journal-title":"Nat Struct Biol"},{"key":"10.1016\/j.coviro.2014.08.004_bib0030","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/S0969-2126(00)80031-3","article-title":"Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus","volume":"7","author":"Ago","year":"1999","journal-title":"Structure"},{"key":"10.1016\/j.coviro.2014.08.004_sbref0035","doi-asserted-by":"crossref","first-page":"13034","DOI":"10.1073\/pnas.96.23.13034","article-title":"Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus","volume":"96","author":"Bressanelli","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coviro.2014.08.004_bib0040","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jmb.2011.10.001","article-title":"An objective assessment of conformational variability in complexes of hepatitis C virus polymerase with non-nucleoside inhibitors","volume":"414","author":"Caillet-Saguy","year":"2011","journal-title":"J Mol Biol"},{"key":"10.1016\/j.coviro.2014.08.004_sbref0045","doi-asserted-by":"crossref","first-page":"20535","DOI":"10.1074\/jbc.M801490200","article-title":"A locking mechanism regulates RNA synthesis and host protein interaction by the hepatitis C virus polymerase","volume":"283","author":"Chinnaswamy","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.coviro.2014.08.004_bib0050","doi-asserted-by":"crossref","first-page":"7107","DOI":"10.1128\/JVI.00459-12","article-title":"Two crucial early steps in RNA synthesis by the hepatitis C virus polymerase involve a dual role of residue 405","volume":"86","author":"Scrima","year":"2012","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2014.08.004_bib0055","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1006\/viro.2001.0948","article-title":"A novel mechanism to ensure terminal initiation by hepatitis C virus NS5B polymerase","volume":"285","author":"Hong","year":"2001","journal-title":"Virology"},{"key":"10.1016\/j.coviro.2014.08.004_sbref0060","doi-asserted-by":"crossref","first-page":"46094","DOI":"10.1074\/jbc.C100349200","article-title":"Hepatitis C virus RNA-dependent RNA polymerase (NS5B) as a mediator of the antiviral activity of ribavirin","volume":"276","author":"Maag","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.coviro.2014.08.004_bib0065","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0022-2836(03)00613-2","article-title":"Multiple interactions within the hepatitis C virus RNA polymerase repress primer-dependent RNA synthesis","volume":"330","author":"Ranjith-Kumar","year":"2003","journal-title":"J Mol Biol"},{"key":"10.1016\/j.coviro.2014.08.004_bib0070","doi-asserted-by":"crossref","first-page":"6503","DOI":"10.1128\/JVI.00386-12","article-title":"Structure of hepatitis C virus polymerase in complex with primer-template RNA","volume":"86","author":"Mosley","year":"2012","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2014.08.004_bib0075","doi-asserted-by":"crossref","first-page":"7705","DOI":"10.1074\/jbc.M709563200","article-title":"Structural insights into mechanisms of catalysis and inhibition in Norwalk virus polymerase","volume":"283","author":"Zamyatkin","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.coviro.2014.08.004_sbref0080","doi-asserted-by":"crossref","first-page":"10674","DOI":"10.1074\/jbc.M111.325530","article-title":"Assembly, purification, and pre-steady-state kinetic analysis of active RNA-dependent RNA polymerase elongation complex","volume":"287","author":"Jin","year":"2012","journal-title":"J Biol Chem"},{"key":"10.1016\/j.coviro.2014.08.004_bib0085","doi-asserted-by":"crossref","first-page":"20509","DOI":"10.1073\/pnas.1105797108","article-title":"Contribution of a mutational bias in hepatitis C virus replication to the genetic barrier in the development of drug resistance","volume":"108","author":"Powdrill","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coviro.2014.08.004_bib0090","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1021\/jo01342a042","article-title":"3\u2032-Deoxynucleosides. IV. Pyrimidine 3\u2032-deoxynucleosides","volume":"31","author":"Walton","year":"1966","journal-title":"J Org Chem"},{"key":"10.1016\/j.coviro.2014.08.004_bib0095","first-page":"41","article-title":"A new synthesis of 2\u2032-C-methylnucleosides starting from d-ribose","author":"Beigelman","year":"1987","journal-title":"Nucleic Acids Symp Ser"},{"key":"10.1016\/j.coviro.2014.08.004_bib0100","first-page":"1700","article-title":"Substrate properties of C\u2032-methylnucleoside triphosphates in a reaction of RNA synthesis catalyzed by Escherichia coli RNA-polymerase","volume":"23","author":"Savochkina","year":"1989","journal-title":"Mol Biol (Mosk)"},{"key":"10.1016\/j.coviro.2014.08.004_bib0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0166-3542(03)00174-8","article-title":"Bovine viral diarrhea virus as a surrogate model of hepatitis C virus for the evaluation of antiviral agents","volume":"60","author":"Buckwold","year":"2003","journal-title":"Antiviral Res"},{"key":"10.1016\/j.coviro.2014.08.004_bib0110","unstructured":"Carroll SS, LaFemina R, Hall DL, Himmelberger AL, Kuo LC, et al.: Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase. Patent number WO\/2002\/057425; 2002."},{"key":"10.1016\/j.coviro.2014.08.004_bib0115","unstructured":"Sommadossi JP, La Colla P: Methods and compositions for treating hepatitis C virus. Patent number WO\/2001\/090121; 2001."},{"key":"10.1016\/j.coviro.2014.08.004_bib0120","unstructured":"Sommadossi JP, La Colla P: Methods and compositions for treating flaviviruses and pestiviruses. Patent number WO\/2001\/092282; 2001."},{"key":"10.1016\/j.coviro.2014.08.004_bib0125","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0168-8278(03)80421-X","article-title":"NM 283 has potent antiviral activity against genotype 1 chronic hepatitis C virus (HCV-1) infection in the chimpanzee","volume":"38","author":"Standring","year":"2003","journal-title":"J Hepatol"},{"key":"10.1016\/j.coviro.2014.08.004_bib0130","first-page":"866A","article-title":"Efficacy and safety of valopicitabine in combination with pegylated interferon-alpha (pegIFN) and ribavirin (RBV) in patients with chronic hepatitis C","volume":"46","author":"Poordad","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.coviro.2014.08.004_sbref0135","doi-asserted-by":"crossref","first-page":"11979","DOI":"10.1074\/jbc.M210914200","article-title":"Inhibition of hepatitis C virus RNA replication by 2\u2032-modified nucleoside analogs","volume":"278","author":"Carroll","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.coviro.2014.08.004_bib0140","doi-asserted-by":"crossref","first-page":"3944","DOI":"10.1128\/AAC.48.10.3944-3953.2004","article-title":"A 7-deaza-adenosine analog is a potent and selective inhibitor of hepatitis C virus replication with excellent pharmacokinetic properties","volume":"48","author":"Olsen","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2014.08.004_bib0145","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1128\/AAC.01032-08","article-title":"Robust antiviral efficacy upon administration of a nucleoside analog to hepatitis C virus-infected chimpanzees","volume":"53","author":"Carroll","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2014.08.004_bib0150","doi-asserted-by":"crossref","first-page":"4161","DOI":"10.1128\/AAC.00433-06","article-title":"General catalytic deficiency of hepatitis C virus RNA polymerase with an S282T mutation and mutually exclusive resistance towards 2\u2032-modified nucleotide analogues","volume":"50","author":"Dutartre","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2014.08.004_bib0155","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1128\/AAC.49.5.2059-2069.2005","article-title":"Replication fitness and NS5B drug sensitivity of diverse hepatitis C virus isolates characterized by using a transient replication assay","volume":"49","author":"Ludmerer","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2014.08.004_bib0160","doi-asserted-by":"crossref","first-page":"49164","DOI":"10.1074\/jbc.M305041200","article-title":"Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro","volume":"278","author":"Migliaccio","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.coviro.2014.08.004_sbref0165","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1021\/jm00086a013","article-title":"Synthesis and anti-HIV activity of 4\u2032-azido- and 4\u2032-methoxynucleosides","volume":"35","author":"Maag","year":"1992","journal-title":"J Med Chem"},{"key":"10.1016\/j.coviro.2014.08.004_bib0170","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1074\/jbc.M510195200","article-title":"The novel nucleoside analog R1479 (4\u2032-azidocytidine) is a potent inhibitor of NS5B-dependent RNA synthesis and hepatitis C virus replication in cell culture","volume":"281","author":"Klumpp","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1016\/j.coviro.2014.08.004_bib0175","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.virol.2006.03.045","article-title":"In vitro selected Con1 subgenomic replicons resistant to 2\u2032-C-methyl-cytidine or to R1479 show lack of cross resistance","volume":"351","author":"Le Pogam","year":"2006","journal-title":"Virology"},{"key":"10.1016\/j.coviro.2014.08.004_bib0180","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/hep.22321","article-title":"Robust antiviral activity of R1626, a novel nucleoside analog: a randomized, placebo-controlled study in patients with chronic hepatitis C","volume":"48","author":"Roberts","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.coviro.2014.08.004_bib0185","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S1665-2681(19)31482-6","article-title":"Balapiravir plus peginterferon alfa-2a (40kD)\/ribavirin in a randomized trial of hepatitis C genotype 1 patients","volume":"11","author":"Nelson","year":"2012","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.coviro.2014.08.004_bib0190","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1074\/jbc.M708929200","article-title":"2\u2032-Deoxy-4\u2032-azido nucleoside analogs are highly potent inhibitors of hepatitis C virus replication despite the lack of 2\u2032-alpha-hydroxyl groups","volume":"283","author":"Klumpp","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.coviro.2014.08.004_bib0195","doi-asserted-by":"crossref","first-page":"4250","DOI":"10.1016\/j.bmcl.2009.05.099","article-title":"The application of phosphoramidate ProTide technology to the potent anti-HCV compound 4\u2032-azidocytidine (R1479)","volume":"19","author":"McGuigan","year":"2009","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.coviro.2014.08.004_bib0200","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1021\/jm801595c","article-title":"The design, synthesis, and antiviral activity of monofluoro and difluoro analogues of 4\u2032-azidocytidine against hepatitis C virus replication: the discovery of 4\u2032-azido-2\u2032-deoxy-2\u2032-fluorocytidine and 4\u2032-azido-2\u2032-dideoxy-2\u2032,2\u2032-difluorocytidine","volume":"52","author":"Smith","year":"2009","journal-title":"J Med Chem"},{"key":"10.1016\/j.coviro.2014.08.004_bib0205","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1016\/j.bmcl.2007.02.004","article-title":"Design, synthesis, and antiviral properties of 4\u2032-substituted ribonucleosides as inhibitors of hepatitis C virus replication: the discovery of R1479","volume":"17","author":"Smith","year":"2007","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.coviro.2014.08.004_sbref0210","doi-asserted-by":"crossref","first-page":"e1003030","DOI":"10.1371\/journal.ppat.1003030","article-title":"Sensitivity of mitochondrial transcription and resistance of RNA polymerase II dependent nuclear transcription to antiviral ribonucleosides","volume":"8","author":"Arnold","year":"2012","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2014.08.004_bib0215","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1128\/AAC.48.2.651-654.2004","article-title":"Inhibition of the subgenomic hepatitis C virus replicon in huh-7 cells by 2\u2032-deoxy-2\u2032-fluorocytidine","volume":"48","author":"Stuyver","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2014.08.004_bib0220","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1177\/095632020601700203","article-title":"Inhibition of hepatitis C replicon RNA synthesis by beta-d-2\u2032-deoxy-2\u2032-fluoro-2\u2032-C-methylcytidine: a specific inhibitor of hepatitis C virus replication","volume":"17","author":"Stuyver","year":"2006","journal-title":"Antiviral Chem Chemother"},{"key":"10.1016\/j.coviro.2014.08.004_sbref0225","doi-asserted-by":"crossref","first-page":"29812","DOI":"10.1074\/jbc.M705274200","article-title":"Characterization of the metabolic activation of hepatitis C virus nucleoside inhibitor beta-d-2\u2032-deoxy-2\u2032-fluoro-2\u2032-C-methylcytidine (PSI-6130) and identification of a novel active 5\u2032-triphosphate species","volume":"282","author":"Ma","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.coviro.2014.08.004_bib0230","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1128\/AAC.01184-07","article-title":"The mechanism of action of beta-d-2\u2032-deoxy-2\u2032-fluoro-2\u2032-C-methylcytidine involves a second metabolic pathway leading to beta-d-2\u2032-deoxy-2\u2032-fluoro-2\u2032-C-methyluridine 5\u2032-triphosphate, a potent inhibitor of the hepatitis C virus RNA-dependent RNA polymerase","volume":"52","author":"Murakami","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2014.08.004_bib0235","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.4155\/fmc.09.88","article-title":"Nucleoside analog inhibitors of hepatitis C viral replication: recent advances, challenges and trends","volume":"1","author":"Furman","year":"2009","journal-title":"Future Med Chem"},{"key":"10.1016\/j.coviro.2014.08.004_bib0240","doi-asserted-by":"crossref","first-page":"7202","DOI":"10.1021\/jm100863x","article-title":"Discovery of a beta-d-2\u2032-deoxy-2\u2032-alpha-fluoro-2\u2032-beta-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus","volume":"53","author":"Sofia","year":"2010","journal-title":"J Med Chem"},{"issue":"7","key":"10.1016\/j.coviro.2014.08.004_bib0245","doi-asserted-by":"crossref","first-page":"3636","DOI":"10.1128\/AAC.02666-14","article-title":"Efficiency of incorporation and chain termination determines the inhibition potency of 2\u2032-modified nucleotide analogs against HCV polymerase","volume":"58","author":"Fung","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2014.08.004_bib0250","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.bcp.2014.04.005","article-title":"Current race in the development of DAAs (direct-acting antivirals) against HCV","volume":"89","author":"De Clercq","year":"2014","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.coviro.2014.08.004_bib0255","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1021\/jm201384j","article-title":"Nucleoside, nucleotide, and non-nucleoside inhibitors of hepatitis C virus NS5B RNA-dependent RNA-polymerase","volume":"55","author":"Sofia","year":"2012","journal-title":"J Med Chem"},{"key":"10.1016\/j.coviro.2014.08.004_bib0260","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1016\/j.bmcl.2014.04.050","article-title":"Synthesis of 2\u2032-O,4\u2032-C-alkylene-bridged ribonucleosides and their evaluation as inhibitors of HCV NS5B polymerase","volume":"24","author":"Chapron","year":"2014","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.coviro.2014.08.004_bib0265","unstructured":"Girijavallabhan V, Njoroge FG, Bogen S, Verma V, Bennett F, et al.: 2\u2032-Substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases. Patent number WO\/2012\/142085; 2012."},{"issue":"Pt 9","key":"10.1016\/j.coviro.2014.08.004_bib0270","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1099\/0022-1317-72-9-2197","article-title":"The phylogeny of RNA-dependent RNA polymerases of positive-strand RNA viruses","volume":"72","author":"Koonin","year":"1991","journal-title":"J Gen Virol"},{"key":"10.1016\/j.coviro.2014.08.004_bib0275","doi-asserted-by":"crossref","DOI":"10.1007\/s00018-014-1695-z","article-title":"Common and unique features of viral RNA-dependent polymerases","author":"Te Velthuis","year":"2014","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.coviro.2014.08.004_bib0280","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1177\/095632020701800406","article-title":"2\u2032-C-Methyl branched pyrimidine ribonucleoside analogues: potent inhibitors of RNA virus replication","volume":"18","author":"Benzaria","year":"2007","journal-title":"Antiviral Chem Chemother"},{"key":"10.1016\/j.coviro.2014.08.004_bib0285","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.antiviral.2010.03.004","article-title":"Efficacy of 2\u2032-C-methylcytidine against yellow fever virus in cell culture and in a hamster model","volume":"86","author":"Julander","year":"2010","journal-title":"Antiviral Res"},{"key":"10.1016\/j.coviro.2014.08.004_bib0290","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1128\/AAC.02393-14","article-title":"Inhibitors of the tick-borne, hemorrhagic fever-associated flaviviruses","volume":"58","author":"Flint","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2014.08.004_bib0295","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.bbrc.2012.10.003","article-title":"Inhibition of norovirus replication by the nucleoside analogue 2\u2032-C-methylcytidine","volume":"427","author":"Rocha-Pereira","year":"2012","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.coviro.2014.08.004_bib0300","doi-asserted-by":"crossref","first-page":"11798","DOI":"10.1128\/JVI.02064-13","article-title":"The viral polymerase inhibitor 2\u2032-C-methylcytidine inhibits Norwalk virus replication and protects against norovirus-induced diarrhea and mortality in a mouse model","volume":"87","author":"Rocha-Pereira","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2014.08.004_bib0305","article-title":"Proof of concept for the inhibition of foot-and-mouth disease virus replication by the anti-viral drug 2\u2032-C-methylcytidine in severe combined immunodeficient mice","author":"Lefebvre","year":"2013","journal-title":"Transbound Emerg Dis"},{"key":"10.1016\/j.coviro.2014.08.004_bib0310","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.antiviral.2010.05.003","article-title":"Biochemical characterization of the inhibition of the dengue virus RNA polymerase by beta-d-2\u2032-ethynyl-7-deaza-adenosine triphosphate","volume":"87","author":"Latour","year":"2010","journal-title":"Antiviral Res"},{"key":"10.1016\/j.coviro.2014.08.004_sbref0315","doi-asserted-by":"crossref","first-page":"20435","DOI":"10.1073\/pnas.0907010106","article-title":"An adenosine nucleoside inhibitor of dengue virus","volume":"106","author":"Yin","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coviro.2014.08.004_bib0320","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1093\/infdis\/jis470","article-title":"A randomized, double-blind placebo controlled trial of balapiravir, a polymerase inhibitor, in adult dengue patients","volume":"207","author":"Nguyen","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2014.08.004_bib0325","doi-asserted-by":"crossref","first-page":"8632","DOI":"10.1021\/jm2011673","article-title":"Phosphorodiamidates as a promising new phosphate prodrug motif for antiviral drug discovery: application to anti-HCV agents","volume":"54","author":"McGuigan","year":"2011","journal-title":"J Med Chem"}],"container-title":["Current Opinion in Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625714001692?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625714001692?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,15]],"date-time":"2019-08-15T04:01:32Z","timestamp":1565841692000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879625714001692"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":65,"alternative-id":["S1879625714001692"],"URL":"https:\/\/doi.org\/10.1016\/j.coviro.2014.08.004","relation":{},"ISSN":["1879-6257"],"issn-type":[{"value":"1879-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibition of viral RNA polymerases by nucleoside and nucleotide analogs: therapeutic applications against positive-strand RNA viruses beyond hepatitis C virus","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coviro.2014.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}